Prediction of Patients Who Can Benefit from Oral Intestinal Sorbent AST-120

다국어 초록 (Multilingual Abstract)

Indoxyl sulfate (IS) increases the expression of fibrogenic genes while it impairs anti- oxidative systems and down-regulates Klotho expression in the kidney. AST-120, which adsorbs uremic toxins and precursors including indole, can decrease serum and urinary levels of IS, the levels of advanced glycation end products (AGEs), and 8-hydroxydeoxyguanosine while it increases the renal expression of Klotho. In addition to the improvement of glomerular sclerosis, serum creatinine levels, and the survival in chronic kidney disease (CKD) animal models, AST-120 alleviated uremic symptoms and slowed the progression of renal dysfunction through small clinical investigations. There have been large clinical studies using AST-120.1-3 But they only recruited patients with advanced renal dysfunction and failed to prove the effectiveness of AST-120 except that Carbonaceous oral Adsorbent's effectiveness on Progression of CKD study showed less decrease of the estimated glomerular filtration rate (eGFR) in the AST-120 group.1

참고문헌 (Reference)

1 차란희, "Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: post-hoc analysis of the Kremezin Study against renal disease progression in Korea" 대한신장학회 36 (36): 68-78, 2017

2 Schulman G, "Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120" 22 (22): 299-308, 2018

3 Schulman G, "Randomized placebo-controlled EPPIC trials of AST-120 in CKD" 26 (26): 1732-1746, 2015

4 Shoji T, "Prospective randomized study evaluating the efficacy of the spherical adsorptive carbon AST-120 in chronic kidney disease patients with moderate decrease in renal function" 105 (105): c99-c107, 2007

5 황유철, "Predictive Factors for Efficacy of AST-120 Treatment in Diabetic Nephropathy: a Prospective Single- Arm, Open-Label, Multi-Center Study" 대한의학회 34 (34): 1-9, 2019

6 Maeda K, "Long-term effects of the oral adsorbent, AST-120, in patients with chronic renal failure" 37 (37): 205-213, 2009

7 Akizawa T, "Effect of a carbonaceous oral adsorbent on the progression of CKD : a multicenter, randomized, controlled trial" 54 (54): 459-467, 2009

8 Cha RH, "A randomized, controlled trial of oral intestinal sorbent AST-120 on renal function deterioration in patients with advanced renal dysfunction" 11 (11): 559-567, 2016